; and (B) doing 2 or more of the following: (i) Implementing substantial improvements in regulations involving the chemical and pharmaceutical production and export of illicit opioids. (ii) Implementing substantial improvements in judicial regulations to combat transnational criminal organizations that traffic opioids. (iii) Increasing efforts to prosecute foreign opioid traffickers. (iv) Increasing intelligence sharing and law enforcement cooperation with the United States with respect to opioid trafficking. (3) Subsequent renewal of waiver The President may renew a waiver under paragraph (1) for subsequent periods of not more than 6 months each if, not less than 30 days before the renewal is to take effect, the Director of National Intelligence certifies to the appropriate congressional committees and leadership that the government of the country to which the waiver applies has effectively implemented and is effectively enforcing the measures that formed the basis for the certification under paragraph (2). (b) Waivers for national security and access to prescription medications (1) In general The President may waive the application of sanctions under this title with respect to a person if the President determines that the application of such sanctions with respect to that person would significantly harm— (A) the national security of the United States